NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68001-0510-85 | 68001-0510 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Aug 13, 2021 | In Use | ||
25021-0462-74 | 25021-0462 | fulvestrant | fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Aug 1, 2019 | Apr 30, 2023 | In Use | |
00310-0720-10 | 00310-0720 | Fulvestrant | Faslodex | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Nov 1, 2010 | In Use | ||
71288-0555-86 | 71288-0555 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Nov 21, 2019 | Jan 31, 2027 | In Use | |
63020-0210-21 | 63020-0210 | Fruquintinib | Fruzaqla | 1.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Nov 8, 2023 | In Use | |
63020-0225-21 | 63020-0225 | Fruquintinib | Fruzaqla | 5.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Nov 8, 2023 | In Use | |
69639-0105-01 | 69639-0105 | Fosnetupitant and Palonosetron | AKYNZEO | 260.0 mg/20mL, 0.28 mg/20mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Intravenous | Jun 15, 2020 | In Use | |
69639-0106-01 | 69639-0106 | Fosnetupitant and Palonosetron | AKYNZEO | 260.0 mg/20mL, 0.28 mg/20mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist, Substance P/Neurokinin 1 | Intravenous | Aug 1, 2023 | In Use | |
69639-0102-01 | 69639-0102 | Fosnetupitant and Palonosetron | AKYNZEO | 260.0 mg/1, 0.28 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Intravenous | Apr 20, 2018 | In Use | |
43598-0948-11 | 43598-0948 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Jul 1, 2020 | In Use | |
71839-0104-01 | 71839-0104 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Oct 15, 2019 | In Use | |
16729-0240-03 | 16729-0240 | FOSAPREPITANT | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Oct 22, 2020 | In Use | |
72603-0450-01 | 72603-0450 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Apr 1, 2025 | In Use | |
68001-0421-22 | 68001-0421 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov 20, 2019 | In Use | |
63323-0972-10 | 63323-0972 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sep 5, 2019 | In Use | |
72205-0083-01 | 72205-0083 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | May 12, 2020 | In Use | |
71288-0418-10 | 71288-0418 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov 15, 2019 | Mar 30, 2023 | No Longer Used |
69539-0034-01 | 69539-0034 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sep 5, 2019 | In Use | |
69539-0181-01 | 69539-0181 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb 10, 2020 | In Use | |
68180-0690-01 | 68180-0690 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sep 25, 2020 | Jan 31, 2024 | No Longer Used |
82243-1001-01 | 82243-1001 | FOSAPREPITANT | FOCINVEZ | 150.0 mg/50mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Aug 30, 2023 | In Use | |
43598-0859-11 | 43598-0859 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sep 6, 2019 | In Use | |
70710-1615-01 | 70710-1615 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov 1, 2020 | In Use | |
72603-0106-01 | 72603-0106 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sep 5, 2019 | Oct 1, 2022 | No Longer Used |
43598-0671-11 | 43598-0671 | Fosaprepitant | Fosaprepitant | 150.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Mar 20, 2020 | In Use |
Found 11564 results — Export these results